Protection of the myocardial cell during ischemia
- PMID: 10482174
- DOI: 10.1016/s0002-9149(99)00246-5
Protection of the myocardial cell during ischemia
Abstract
Prevention of myocardial necrosis in acute coronary syndromes is the immediate goal of therapy. Decreasing myocardial oxygen needs is of marginal value. Improving oxygen delivery by mechanical or thrombolytic reperfusion is more successful but still leaves much to be desired in terms of time to reperfusion before damage occurs due to reperfusion itself. During ischemia, there is a metabolic mismatch between glycolysis and glucose oxidation that results in accumulation of hydrogen ions, which, in turn, activates the Na+/H+ exchange system (NHE-1), leading to Na+ and Ca2+ overload and cell death. Blocking NHE-1 is a new strategy designed to prevent or delay cell death. Cariporide, a potent inhibitor of the NHE-1 system, is currently under investigation. Other agents under investigation are designed to modify proton generation, modify proton effects, and attenuate necrosis progression. Also under study are agents designed to mediate preconditioning (adenosine agonists and adenosine triphosphate-sensitive potassium channel openers). Other approaches to minimize cell injury include use of antioxidants and free-radical scavengers, complement inhibitors, selectin blockers, and glycoprotein (GP) IIb/IIIa antagonists.
Similar articles
-
Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia.Am J Cardiol. 1999 May 20;83(10A):10G-17G; discussion 17G-18G. doi: 10.1016/s0002-9149(99)00215-5. Am J Cardiol. 1999. PMID: 10482175 Review.
-
Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.Am J Cardiol. 1999 May 20;83(10A):19G-22G. doi: 10.1016/s0002-9149(99)00316-1. Am J Cardiol. 1999. PMID: 10482176 Review.
-
A symposium: sodium-hydrogen exchange inhibition. Introduction.Am J Cardiol. 1999 May 20;83(10A):1G-2G. doi: 10.1016/s0002-9149(99)00214-3. Am J Cardiol. 1999. PMID: 10482173 No abstract available.
-
GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes.Am J Cardiol. 1999 May 20;83(10A):23G-25G. doi: 10.1016/s0002-9149(99)00216-7. Am J Cardiol. 1999. PMID: 10482177 Clinical Trial.
-
Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury.Eur J Pharmacol. 2000 Sep 15;404(1-2):221-9. doi: 10.1016/s0014-2999(00)00613-0. Eur J Pharmacol. 2000. PMID: 10980282
Cited by
-
Substrate dependence of the postischemic cardiomyocyte recovery: dissociation between functional, metabolic and injury markers.Mol Cell Biochem. 2005 May;273(1-2):43-55. doi: 10.1007/s11010-005-7375-4. Mol Cell Biochem. 2005. PMID: 16013439
-
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial.Curr Control Trials Cardiovasc Med. 2000;1(1):59-67. doi: 10.1186/cvm-1-1-059. Curr Control Trials Cardiovasc Med. 2000. PMID: 11714411 Free PMC article.
-
Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats.J Pharm Pharmacol. 2014 Sep;66(9):1251-8. doi: 10.1111/jphp.12251. Epub 2014 Apr 2. J Pharm Pharmacol. 2014. PMID: 24697323 Free PMC article.
-
Effects of aminoguanidine and melatonin on intestinal ischemia/reperfusion injury in rats: An assessor-blinded, controlled experimental study.Curr Ther Res Clin Exp. 2009 Dec;70(6):449-59. doi: 10.1016/j.curtheres.2009.12.002. Curr Ther Res Clin Exp. 2009. PMID: 24692837 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous